Raymond John Playford

List of Publications by Year
in descending order

140 papers	8,405 citations	44069 48 h-index	48315 88 g-index
142 all docs	142 docs citations	142 times ranked	8712 citing authors

#	Article	IF	Citations
1	Intralesional Infiltrations of Arteriosclerotic Tissue Cells-Free Filtrate Reproduce Vascular Pathology in Healthy Recipient Rats. International Journal of Molecular Sciences, 2022, 23, 1511.	4.1	1
2	The Use of Bovine Colostrum in Medical Practice and Human Health: Current Evidence and Areas Requiring Further Examination. Nutrients, 2022, 14, 92.	4.1	5
3	Bovine Colostrum: Its Constituents and Uses. Nutrients, 2021, 13, 265.	4.1	102
4	Effects of Bovine Colostrum with or without Egg on In Vitro Bacterial-Induced Intestinal Damage with Relevance for SIBO and Infectious Diarrhea. Nutrients, 2021, 13, 1024.	4.1	11
5	Oral zinc carnosine reduces multi-organ damage caused by gut ischemia/reperfusion in mice. Journal of Functional Foods, 2021, 78, 104361.	3.4	4
6	Intralesional Infiltrations of Cell-Free Filtrates Derived from Human Diabetic Tissues Delay the Healing Process and Recreate Diabetes Histopathological Changes in Healthy Rats. Frontiers in Clinical Diabetes and Healthcare, 2021, 2, .	0.8	4
7	Methods to improve efficacy of orally administered bioactive peptides using bovine colostrum as an exemplar. PLoS ONE, 2021, 16, e0253422.	2.5	3
8	Protease Inhibitors Protect Bovine Colostrum or Chicken Egg Growth Factors from Pancreatic Enzyme Digestion in AGS Cells or Colitic Rats. Journal of Nutrition, 2021, 151, 3036-3044.	2.9	3
9	Oral bovine colostrum supplementation does not increase circulating insulin-like growth factor-1 concentration in healthy adults: results from short- and long-term administration studies. European Journal of Nutrition, 2020, 59, 1473-1479.	3.9	15
10	Pancreatic secretory trypsin inhibitor reduces multi-organ injury caused by gut ischemia/reperfusion in mice. PLoS ONE, 2020, 15, e0227059.	2.5	6
11	Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials. PLoS ONE, 2020, 15, e0234719.	2.5	22
12	Review: Insulin resistance and mitochondrial dysfunction following severe burn injury. Peptides, 2020, 126, 170269.	2.4	10
13	Pasteurized Chicken Egg Powder Stimulates Proliferation and Migration of AGS, RIE1, and Caco-2 Cells and Reduces NSAID-Induced Injury in Mice and Colitis in Rats. Journal of Nutrition, 2020, 150, 1434-1442.	2.9	14
14	TAME trial: a multi-arm phase II randomised trial of four novel interventions for malnutrition enteropathy in Zambia and Zimbabwe - a study protocol. BMJ Open, 2019, 9, e027548.	1.9	5
15	Trefoil factor family peptides enhance cell migration by increasing cellular osmotic permeability and aquaporin 3 levels. FASEB Journal, 2018, 32, 1017-1024.	0.5	10
16	Specific protein supplementation using soya, casein or whey differentially affects regional gut growth and luminal growth factor bioactivity in rats; implications for the treatment of gut injury and stimulating repair. Food and Function, 2018, 9, 227-233.	4.6	1
17	Intestinal fatty acid-binding protein and gut permeability responses to exercise. European Journal of Applied Physiology, 2017, 117, 931-941.	2.5	62
18	Zinc carnosine works with bovine colostrum in truncating heavy exerciseâ€“induced increase in gut permeability in healthy volunteers. American Journal of Clinical Nutrition, 2016, 104, 526-536.	4.7	57

#	Article	IF	Citations
19	Pancreatic secretory trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2. American Journal of Physiology - Renal Physiology, 2013, 305, F382-F389.	2.7	19
20	Use of the Alpha-Glucosidase Inhibitor Acarbose in Patients with â€˜Middleton Syndromeâ€™: Normal Gastric Anatomy But with Accelerated Gastric Emptying Causing Postprandial Reactive Hypoglycemia and Diarrhea. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 403-404.	1.7	25
21	IL-1Î² stimulation of CCD-18co myofibroblasts enhances repair of epithelial monolayers through Wnt-5a. American Journal of Physiology - Renal Physiology, 2012, 303, G1270-G1278.	3.4	9
22	Dimethyloxalylglycine stimulates the early stages of gastrointestinal repair processes through VEGF-dependent mechanisms. Laboratory Investigation, 2011, 91, 1684-1694.	3.7	20
23	Reparative properties of the traditional Chinese medicine Cordyceps sinensis (Chinese) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Journal of Nutrition, 2011, 105, 1303-1310.	2.3	20
24	The nutriceutical bovine colostrum truncates the increase in gut permeability caused by heavy exercise in athletes. American Journal of Physiology - Renal Physiology, 2011, 300, G477-G484.	3.4	118
25	Pancreatic secretory trypsin inhibitor is a major motogenic and protective factor in human breast milk. American Journal of Physiology - Renal Physiology, 2009, 296, G697-G703.	3.4	25
26	Integration of ERG gene mapping and geneâ€expression profiling identifies distinct categories of human prostate cancer. BJU International, 2009, 103, 1256-1269.	2.5	54
27	Intestinal protective effect of a commercial fish protein hydrolysate preparation. Regulatory Peptides, 2009, 155, 105-109.	1.9	23
28	What is the role of growth factors in IBD?. Inflammatory Bowel Diseases, 2008, 14, S119-S120.	1.9	2
29	Newly identified genetic risk variants for celiac disease related to the immune response. Nature Genetics, 2008, 40, 395-402.	21.4	599
30	Clinical trial: protective effect of a commercial fish protein hydrolysate against indomethacin (NSAID)â€induced small intestinal injury. Alimentary Pharmacology and Therapeutics, 2008, 28, 799-804.	3.7	46
31	What is the role of growth factors in IBD?. Inflammatory Bowel Diseases, 2008, 14, S119-S120.	1.9	0
32	Comparison of cytokine modulation by natural peroxisome proliferatorâ€“activated receptor Î³ ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cellsâ€”potential for dietary modulation of peroxisome proliferatorâ€“activated receptor Î³ in intestinal inflammation. American Journal of Clinical Nutrition, 2008, 87, 939-948.	4.7	107
33	Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut, 2007, 56, 168-175.	12.1	88
34	Human Pancreatic Secretory Trypsin Inhibitor Stabilizes Intestinal Mucosa against Noxious Agents. American Journal of Pathology, 2007, 171, 1462-1473.	3.8	12
35	NOD2 activity modulates the phenotype of LPS-stimulated dendritic cells to promote the development of T-helper type 2-like lymphocytes â€” Possible implications for NOD2-associated Crohn's disease. Journal of Crohn's and Colitis, 2007, 1, 106-115.	1.3	17
36	A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nature Genetics, 2007, 39, 827-829.	21.4	592

#	Article	IF	Citations
37	Dietary microparticles implicated in Crohnâ€™s disease can impair macrophage phagocytic activity and act as adjuvants in the presence of bacterial stimuli. Inflammation Research, 2007, 56, 353-361.	4.0	38
38	Effects of Mouse and Human Lipocalin Homologues 24p3/lcn2 and Neutrophil Gelatinaseâ€“Associated Lipocalin on Gastrointestinal Mucosal Integrity and Repair. Gastroenterology, 2006, 131, 809-817.	1.3	90
39	Genetic Variation in Myosin IXB Is Associated With Ulcerative Colitis. Gastroenterology, 2006, 131, 1768-1774.	1.3	95
40	Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clinical Science, 2006, 110, 563-573.	4.3	17
41	Detection of muramyl dipeptide-sensing pathway defects in patients with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2006, 12, 598-605.	1.9	21
42	Characterization and Clinical Application of Human CD34 ⁺ Stem/Progenitor Cell Populations Mobilized into the Blood by Granulocyte Colonyâ€Stimulating Factor. Stem Cells, 2006, 24, 1822-1830.	3.2	267
43	Modulation of dendritic cell phenotype and functionin an in vitro model of the intestinal epithelium. European Journal of Immunology, 2006, 36, 864-874.	2.9	71
44	Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease. European Journal of Immunology, 2006, 36, 1629-1635.	2.9	14
45	Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?. Gut, 2006, 55, 6-8.	12.1	46
46	Lack of association of MYO9B genetic variants with coeliac disease in a British cohort. Gut, 2006, 55, 969-972.	12.1	58
47	Bone Marrowâ€“Derived Stromal Cells Express Lineage-Related Messenger RNA Species. Cancer Research, 2006, 66, 1265-1269.	0.9	51
48	Gastroprotective effects of oral nucleotide administration. Gut, 2006, 55, 165-171.	12.1	19
49	New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut, 2006, 55, 442-442.	12.1	222
50	Trial of trefoil factor 3 enemas, in combination with oral 5â€aminosalicylic acid, for the treatment of mildâ€toâ€moderate leftâ€sided ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2005, 21, 1357-1364.	3.7	52
51	A common CTLA4 haplotype associated with coeliac disease. European Journal of Human Genetics, 2005, 13, 440-444.	2.8	76
52	Synergistic enhancement of Toll-like receptor responses by NOD1 activation. European Journal of Immunology, 2005, 35, 2471-2476.	2.9	135
53	Accelerated exposure of phosphatidylserine on lymphocyte populations from patients with systemic lupus erythematosus or rheumatoid arthritis. Thrombosis and Haemostasis, 2005, 93, 989-992.	3.4	1
54	Intestinal Growth in Parenterallyâ€Fed Rats Induced by the Combined Effects of Glucagonâ€like Peptide 2 and Epidermal Growth Factor. Journal of Parenteral and Enteral Nutrition, 2005, 29, 248-254.	2.6	27

#	Article	IF	Citations
55	Reparative properties of a commercial fish protein hydrolysate preparation. Gut, 2005, 54, 775-781.	12.1	69
56	The value of surveillance and other unresolved issues in the management of Barrett's esophagus. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 60-61.	1.7	4
57	Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut, 2005, 54, 1553-1557.	12.1	111
58	Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet, The, 2005, 365, 1794-1796.	13.7	305
59	Interfering with interferons in inflammatory bowel disease. Gut, 2005, 55, 1071-1073.	12.1	29
60	Relevance of Growth Factors for the Gastrointestinal Tract and Other Organs. Nutraceutical Science and Technology, 2005, , 217-241.	0.0	0
61	Probiotics in inflammatory bowel disease: is it all gut flora modulation?. Gut, 2004, 53, 620-622.	12.1	83
62	Effects of growth factors and receptor blockade on gastrointestinal cancer. Gut, 2004, 53, 1059-1063.	12.1	2
63	Growth factors and trefoil peptides in gastrointestinal health and disease. Current Opinion in Pharmacology, 2004, 4, 567-571.	3.5	21
64	Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. Peptides, 2004, 25, 793-801.	2.4	46
65	Development of a two-site ELISA assay for the dimeric form of human TFF1. Peptides, 2004, 25, 731-736.	2.4	4
66	Growth Factors. , 2004, , 249-256.		0
67	Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK. Alimentary Pharmacology and Therapeutics, 2003, 17, 1319-1324.	3.7	54
68	Surveillance for Barrett's oesophagus: is there light at the end of the metaplastic tunnel?. Journal of the Royal College of Surgeons of Edinburgh, 2003, 1, 152-156.	1.8	1
69	Epidermal Growth Factor Enemas with Oral Mesalamine for Mild-to-Moderate Left-Sided Ulcerative Colitis or Proctitis. New England Journal of Medicine, 2003, 349, 350-357.	27.0	296
70	Bioactive natural compounds for the treatment of gastrointestinal disorders. Clinical Science, 2003, 104, 547-556.	4.3	72
71	GERD 2003 â€“ A Consensus on the Way Ahead. Digestion, 2003, 67, 111-117.	2.3	41
72	Homeobox genes: going for growth. Gut, 2002, 50, 447-448.	12.1	0

#	Article	IF	Citations
73	Human transforming growth factor alpha (TGF-alpha) is digested to a smaller (1-43), less biologically active, form in acidic gastric juice. Gut, 2002, 51, 787-792.	12.1	12
74	Cost Analysis of Breath Test versus Endoscopy for Dyspepsia. Digestion, 2002, 65, 207-212.	2.3	6
75	Endoscopic surveillance of patients with Barrett's oesophagus. Gut, 2002, 51, 314-315.	12.1	13
76	Prophylactic Use of Epidermal Growth Factor Reduces Ischemia/Reperfusion Intestinal Damage. American Journal of Pathology, 2002, 161, 373-379.	3.8	73
77	Nitric oxide regulates the release of somatostatin from cultured gastric rabbit primary D-cells. Gastroenterology, 2002, 123, 566-576.	1.3	17
78	Does Helicobacter pylori Eradication Reduce the Long-term Requirements for Acid Suppressants in Patients with a History of Peptic Ulcer Disease in General Practice? Results from a Four-Year Longitudinal Study. Scandinavian Journal of Gastroenterology, 2002, 37, 144-147.	1.5	10
79	Once you start, you can't stop. Lancet, The, 2002, 359, 226.	13.7	3
80	Use of the â€˜nutriceuticalâ€™, bovine colostrum, for the treatment of distal colitis: results from an initial study. Alimentary Pharmacology and Therapeutics, 2002, 16, 1917-1922.	3.7	79
81	Epidermal growth factor enemas are effective in the treatment of left-sided ulcarative colitis. Gastroenterology, 2001, 120, A11-A12.	1.3	7
82	Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. Clinical Science, 2001, 100, 627-633.	4.3	90
83	Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. Clinical Science, 2001, 100, 627.	4.3	51
84	Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut, 2001, 48, 803-807.	12.1	67
85	Epidermal growth factor reduces multiorgan failure induced by thioacetamide. Gut, 2001, 48, 34-40.	12.1	44
86	Landscaper seeks remunerative position. Gut, 2001, 48, 594-595.	12.1	7
87	Effect of Ectopic Expression of Rat Trefoil Factor Family 3 (Intestinal Trefoil Factor) in the Jejunum of Transgenic Mice. Journal of Biological Chemistry, 2001, 276, 24088-24096.	3.4	45
88	Liver biopsy: "blind" or under ultrasound control Reply. Gut, 2001, 49, 157-158.	12.1	0
89	Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. American Journal of Clinical Nutrition, 2000, 72, 5-14.	4.7	330
90	Peptide gene expression in gastrointestinal mucosal ulceration: ordered sequence or redundancy?. Gut, 2000, 46, 286-292.	12.1	68

#	Article	IF	Citations
91	Potency and stability of C terminal truncated human epidermal growth factor. Gut, 2000, 47, 622-627.	12.1	30
92	Liver biopsy under ultrasound control Reply. Gut, 2000, 47, 455-455.	12.1	3
93	Does the response of the intestinal epithelium to keratinocyte growth factor vary according to the method of administration?. Regulatory Peptides, 2000, 87, 83-90.	1.9	14
94	Reprogramming of intestinal differentiation and intercalary regeneration inCdx2mutant mice. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 7318-7323.	7.1	262
95	Bovine colostrum is a health food supplement which prevents NSAID induced gut damage. Gut, 1999, 44, 653-658.	12.1	126
96	Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2316-2321.	7.1	117
97	Liver biopsy under ultrasound control: implications for training in the Calman era. Gut, 1999, 45, 628-629.	12.1	13
98	The mucous neck cell in the human gastric corpus: a distinctive, functional cell lineage. Journal of Pathology, 1999, 187, 331-337.	4.5	46
99	The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. , 1999, 188, 312-317.		68
100	The Trefoil Peptide TFF1 Inhibits the Growth of the Human Gastric Adenocarcinoma Cell Line, AGS. Clinical Science, 1999, 96, 1P-1P.	0.0	0
101	Pantoprazole, Prout and the proton pump. British Journal of Hospital Medicine, 1999, 60, 500-504.	0.2	7
102	Effects of keratinocyte growth factor (KGF) on gut growth and repair. , 1998, 184, 316-322.		43
103	Tales from the human cryptâ€"intestinal stem cell repertoire and the origins of human cancer. , 1998, 185, 119-122.		5
104	Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. , 1998, 185, 153-158.		72
105	Expression of catenins and E-cadherin during epithelial restitution in inflammatory bowel disease. , 1998, 185, 413-418.		121
106	Human Pancreatic Secretory Trypsin Inhibitor. Digestion, 1998, 59, 167-174.	2.3	58
107	Growth factors and gut function. Proceedings of the Nutrition Society, 1998, 57, 403-408.	1.0	10
108	Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. Journal of Pathology, 1998, 185, 153-158.	4.5	1

#	Article	IF	Citations
109	Ten yearsâ€™ experience of screening patients with Barrettâ€™s oesophagus in a university teaching hospital. Gut, 1997, 41, 303-307.	12.1	47
110	Growth factors in saliva. Lancet, The, 1997, 350, 369.	13.7	3
111	Effects of a panel of dietary lectins on cholecystokinin release in rats. American Journal of Physiology - Renal Physiology, 1997, 273, G946-G950.	3.4	6
112	Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis. Trends in Pharmacological Sciences, 1996, 17, 436-438.	8.7	38
113	Comparison of the Effects of Transforming Growth Factor Î± and Epidermal Growth Factor on Gastrointestinal Proliferation and Hormone Release. Digestion, 1996, 57, 362-367.	2.3	31
114	Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 2137-2142.	7.1	168
115	9 Growth factors and ulcerative gastrointestinal disease. Bailliere's Clinical Gastroenterology, 1996, 10, 135-149.	0.9	3
116	The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract.. Gut, 1996, 39, 262-266.	12.1	150
117	Cytokines and Helicobacter pylori--a growth area.. Gut, 1996, 39, 881-882.	12.1	3
118	Why is epidermal growth factor present in the gut lumen?. Gut, 1996, 38, 303-305.	12.1	89
119	Combined Intestinal Trefoil Factor and Epidermal Growth Factor is Prophylactic against Indomethacin-Induced Gastric Damage in the Rat. Clinical Science, 1995, 88, 401-403.	4.3	102
120	Luminal Epidermal Growth Factor is Trophic to the Small Intestine of Parenterally Fed Rats. Clinical Science, 1995, 89, 117-120.	4.3	37
121	Peptides and gastrointestinal mucosal integrity.. Gut, 1995, 37, 595-597.	12.1	92
122	Epidermal growth factor is digested to smaller, less active forms in acidic gastric juice. Gastroenterology, 1995, 108, 92-101.	1.3	111
123	Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology, 1995, 108, 108-116.	1.3	251
124	Epidermal growth factor and intestinal growth. Gastroenterology, 1995, 108, 1330-1331.	1.3	2
125	Is glutamine required for the trophic effect of epidermal growth factor?. Surgery, 1995, 117, 355.	1.9	1
126	Influence of inflammation and atrophy on pancreatic secretory trypsin inhibitor levels within the gastric mucosa. Gastroenterology, 1994, 106, 735-741.	1.3	17

#	Article	IF	Citations
127	Effects of diet and the cholecystokinin antagonist; devazepide (L364, 718) on CCK mRNA, and tissue and plasma CCK concentrations. European Journal of Clinical Investigation, 1993, 23, 641-647.	3.4	5
128	Effect of luminal growth factor preservation on intestinal growth. Lancet, The, 1993, 341, 843-848.	13.7	107
129	Suppression of Helicobacter pylori reduces gastrin releasing peptide stimulated gastrin release in duodenal ulcer patients.. Gut, 1992, 33, 601-603.	12.1	52
130	Whipple's disease complicated by a retinal Jarisch-Herxheimer reaction: a case report.. Gut, 1992, 33, 132-134.	12.1	26
131	pH-Dependent Secretion of Gastrin in Duodenal Ulcer Disease: Effect of Suppressing Helicobacter pylori. Digestion, 1992, 52, 173-178.	2.3	9
132	Effect of chymotrypsin on human cholecystokinin release: use of clostripain in the validation of a new radioimmunoassay. Regulatory Peptides, 1992, 40, 1-12.	1.9	19
133	Hypergastrinaemia: a new mechanism. Lancet, The, 1991, 338, 410-411.	13.7	10
134	Dose-Dependent Effects of Fentanyl on Indomethacin-Induced Gastric Damage. Digestion, 1991, 49, 198-203.	2.3	21
135	Gastric output of pancreatic secretory trypsin inhibitor is increased by misoprostol.. Gut, 1991, 32, 1396-1400.	12.1	25
136	Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice.. Gut, 1990, 31, 1318-1323.	12.1	40
137	Bismuth induced encephalopathy caused by tri potassium dicitrato bismuthate in a patient with chronic renal failure.. Gut, 1990, 31, 359-360.	12.1	55
138	Preliminary report: role of peptide YY in defence against diarrhoea. Lancet, The, 1990, 335, 1555-1557.	13.7	69
139	Right ventricular pacing wire thrombus presenting as pyrexia of unknown origin. Clinical Cardiology, 1989, 12, 106-108.	1.8	10
140	CAMPYLOBACTER PYLORI AND DUODENAL ULCERS: THE GASTRIN LINK. Lancet, The, 1989, 333, 1167-1168.	13.7	333